CHEMILUMINESCENCE IMMUNOASSAY MARKET ANALYSIS

Chemiluminescence Immunoassay Market, By Product Type (Analyzers and Reagents), By Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, Others), By Sample Type (Blood, Urine, Saliva, Other Sample Types), By End User (Hospitals, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024
Code : CMI4656
Pages :210
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Key Developments

In November 2023, Medical & Biological Laboratories Co., Ltd., a JSR Life Sciences Company, launched the "iStar 500," an automated mono-test chemiluminescence immunoassay (CLIA) analyzer worldwide. This compact and highly sensitive analyzer is ideal for emergency and small- to medium-sized labs, offering a wide range of testing parameters including cardiac markers, reproductive health, liver health, tumor markers, and autoimmunity.
In July 2023, Fapon, a prominent global life sciences company, unveiled its newest chemiluminescence immunoassay system, the Shine i8000/9000, at the 2023 AACC exhibition. This advanced analyzer is fully automated and operates at high speed, boasting an ultra-high throughput of 900 tests per hour. It is designed to enable Fapon's partners to develop top-tier clinical diagnostic solutions.
In May 2023, PerkinElmer, a global provider of technology and service solutions, introduced Revvity, a pioneering science-driven solutions company that leverages advanced innovation to improve lives through a diverse array of products
In December 2022, Sysmex obtained approval in Japan for manufacturing and marketing the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit, designed to detect levels of amyloid beta (Aβ) in blood
In June 2020, Abbott, a global healthcare company, initiated supply of its laboratory-based serology blood test for detecting COVID-19 antibodies (IgG) in India. The company is delivering millions of tests to hospitals and labs across Maharashtra, Delhi, West Bengal, Uttar Pradesh, Jammu & Kashmir, and Gujarat, both government and private.